Re: EMPLOYMENT AGREEMENTEmployment Agreement • May 21st, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • New York
This Employment Agreement (the “Agreement”) between you (referred to hereinafter as the “Executive”) and OKYO Pharma Limited, a company incorporated in Guernsey, Channel Islands (the “Company”) sets forth the terms and conditions that shall govern the period of Executive’s continued employment with the Company (referred to hereinafter as “Employment” or the “Employment Period”). Your employing entity for the purposes of the Employment will be OKYO Pharma US Inc., a wholly owned subsidiary of the Company.
AMENDMENT No. 1 TO COLLABORATION AGREEMENT BETWEEN TUFTS MEDICAL CENTER, INC AND OKYO PHARMA LIMITEDCollaboration Agreement • May 21st, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances)
THIS AMENDMENT is entered into as of the date of last signature below by and between Tufts Medical Center, Inc., a not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of business at 800 Washington Street, Boston, MA 02111 (“Tufts MC”), and Okyo Pharma Limited, a limited liability company incorporated and registered in Guernsey whose registered office and principal place of business is at Martello Court, Admiral Park, St. Peter Port, Guernsey GYI 3HB (“OKYO”).
Dated August 6th, 2019 - and - COLLABORATION AGREEMENT FOR THE PROPOSED CORNEAL NEUROPATHIC PAIN PROGRAM COOLEY (UK) LLP, DASHWOOD, 69 OLD BROAD STREET, LONDON EC2M 1QS, UKCollaboration Agreement • May 21st, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • New York
FIRST AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT BY AND BETWEEN ON TARGET THERAPEUTICS LLC AND OKYO PHARMA LIMITEDLicense and Sublicense Agreement • May 21st, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT (“First Amendment”) is dated as of March 25, 2021 (the “First Amendment Effective Date”) by and between On Target Therapeutics, LLC, 15 Wynnewood Road, Wellesley, MA 02481 and (“On Target”) and OKYO Pharma Limited, Martello Court, Admiral Park, St. Peter Port, Guernsey, GY1 3HB (“OKYO”).
